In a filing, MBX Biosciences Inc revealed its President & CEO Hawryluk P. Kent acquired Company’s shares for reported $0.27 million on Oct 20 ’25. In the deal valued at $13.64 per share,20,000 shares were bought. As a result of this transaction, Hawryluk P. Kent now holds 468,277 shares worth roughly $8.17 million.
Then, Hoerter Steven L. bought 20,000 shares, generating $264,984 in total proceeds. Upon buying the shares at $13.25, the Director now owns 20,000 shares.
Before that, Heron Patrick J bought 666,666 shares. MBX Biosciences Inc shares valued at $11,999,988 were divested by the Director at a price of $18.00 per share. As a result of the transaction, Heron Patrick J now holds 5,219,440 shares, worth roughly $91.03 million.
Truist initiated its MBX Biosciences Inc [MBX] rating to a Buy in a research note published on October 15, 2025; the price target was $50. Mizuho began covering MBX with “an Outperform” recommendation on August 05, 2025. Oppenheimer started covering the stock on July 16, 2025. It rated MBX as “an Outperform”.
Price Performance Review of MBX
On Monday, MBX Biosciences Inc [NASDAQ:MBX] saw its stock jump 2.59% to $17.44. Over the last five days, the stock has gained 22.56%. MBX Biosciences Inc shares have fallen nearly -24.60% since the year began. Nevertheless, the stocks have fallen -5.37% over the past one year. While a 52-week high of $27.50 was reached on 09/22/25, a 52-week low of $4.81 was recorded on 04/07/25.
Levels Of Support And Resistance For MBX Stock
The 24-hour chart illustrates a support level at 16.97, which if violated will result in even more drops to 16.49. On the upside, there is a resistance level at 17.86. A further resistance level may holdings at 18.28.
How much short interest is there in MBX Biosciences Inc?
A steep rise in short interest was recorded in MBX Biosciences Inc stocks on 2025-10-15, dropping by -0.32 million shares to a total of 3.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 4.23 million shares. There was a decline of -8.11%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 10, 2025 when Citizens JMP began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $38 price target.
